Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate extended survival by four months compared with chemotherapy.
Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.
The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.
These are the latest cancer treatments approved by the FDA.
“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.
More than half of patients treated with mitomycin experienced complete tumor remission.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.